Ethereum developers postponed the Glamsterdam upgrade on the Hoodi testnet after security firm ChainSecurity found eight smart contract assumptions that could break due to new gas charging rules in EIP-8037 and EIP-8038. These changes affect how gas is charged for creating and accessing blockchain state, potentially causing some contracts to behave unexpectedly or fail safeguards. The Ethereum Foundation is asking developers and auditors to review affected contracts and report issues before deciding on any specification changes. Meanwhile, the Hoodi hard fork remains on hold, but work on the next Hegotá upgrade continues as planned.
Ethereum's Glamsterdam upgrade delay provides context for cryptocurrency market activity as of Nov 06, 2026 20:21 WIB. For readers following major cryptocurrencies on Pluang, 6 out of 50 rose while 43 fell. Notable movers include SXP (Solar) down 46.27% at Rp37, ONE (Harmony) up 33.20% at Rp27 with 84% sell orders, and BAL (Balancer) up 11.14% at Rp16.297.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
